- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05131022
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Phase 1a is a dose escalation to evaluate the safety and tolerability of NX-5948 in adult patients with relapsed/refractory (R/R) B cell malignancies who have received at least 2 prior lines of therapy, or at least 1 prior line of therapy for Primary Central Nervous System Lymphoma (PCNSL), and for whom no other therapies are known to provide clinical benefit. Indications include: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Waldenstrom Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), or Primary Central Nervous System Lymphoma (PCNSL).
Phase 1b will investigate the efficacy of NX-5948 at the dose(s) selected in Phase 1a in up to 7 expansion arms of patients with histologically confirmed R/R B-cell malignancy indications who have received the specified prior therapies based on indication:
- CLL or SLL (two dose levels will be investigated for CLL/SLL)
- MCL
- MZL
- WM
- DLBCL
- FL
- PCNSL/SCNSL
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Patient Outreach
- Phone Number: 7821 +1 (415) 417-3441
- Email: NX5948301@nurixtx.com
Study Locations
-
-
-
Nijmegen, Netherlands, 6525 GA
- Recruiting
- Radboud University Medical Center
-
Rotterdam, Netherlands, 3015 GD
- Recruiting
- Erasmus MC
-
Utrecht, Netherlands, 3584 CX
- Recruiting
- University Medical Center Utrecht
-
-
-
-
-
Leeds, United Kingdom, LS9 7TF
- Recruiting
- St. James Hospital
-
Liverpool, United Kingdom, L7 8YA
- Recruiting
- Clatterbridge Cancer Center NHS Foundation Trust
-
London, United Kingdom, W1G 6AD
- Recruiting
- Sarah Cannon Research Institute UK
-
London, United Kingdom, EC1A 7BE
- Recruiting
- St. Bartholomew's Hospital, Barts NHS Trust
-
Manchester, United Kingdom, M20 4BX
- Recruiting
- The Christie NHS Foundation Trust
-
Oxford, United Kingdom, OX3 7LE
- Recruiting
- Oxford University Hospitals NHS Foundation Trust
-
Plymouth, United Kingdom, PL6 8DH
- Recruiting
- University Hospitals Plymouth NHS Trust
-
Southampton, United Kingdom, SO16 6YD
- Recruiting
- University Hospital Southampton NHS Foundation Trust
-
Sutton, United Kingdom, SM2 5PT
- Recruiting
- Royal Marsden NHS Foundation Trust
-
-
Scotland
-
Glasgow, Scotland, United Kingdom, G12 0YN
- Recruiting
- The Beatson WOS Cancer Center
-
Contact:
- Pam McKay
-
-
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope
-
San Francisco, California, United States, 94143
- Recruiting
- University of California, San Francisco
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Recruiting
- Yale Cancer Center
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- University of Miami
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Winship Cancer Institute of Emory University
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern University
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Recruiting
- Duke University Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Recruiting
- University of Cincinnati Medical Center
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Recruiting
- Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Age ≥18 years
- Patients in Phase 1a (Dose Escalation) must have histologically confirmed R/R CLL, SLL, DLBCL (subgroups include Richter-transformed DLBCL, germinal center B-cell type, activated B-cell type, high-grade B-cell lymphoma with MYC and BCL-2 and/or BCL-6 rearrangements, high-grade B-cell lymphomas NOS), FL, MCL, MZL (subtypes include EMZL, MALT, NMZL, SMZL), WM, or PCNSL.
Patients in Phase 1a must meet the following:
o For non-PCNSL indications, received at least 2 prior lines of therapy and have no other therapies known to provide clinical benefit. For PCNSL, received at least 1 prior line of therapy
- Patients in Phase 1b (Cohort Expansion) must have 1 of the following histologically documented R/R B-cell malignancies, must meet criteria for systemic treatment, and must have received prior therapies based on indication: CLL or SLL, DLBCL, MCL, FL, MZL, WM, or PCNSL/SCNSL.
- Measurable disease per response criteria specific to the malignancy.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (0-2 for patients with PCNSL and secondary CNS involvement).
- Adequate organ and bone marrow function
Key Exclusion Criteria:
- Known or suspected prolymphocytic leukemia or Richter's transformation to Hodgkin's lymphoma at any time preceding enrollment
Prior treatment for the indication under study for anti-cancer intent that includes:
- Radiotherapy within 2 weeks of planned start of study drug (excluding limited palliative radiation).
- Prior systemic chemotherapy within 2 weeks of planned start of study drug. Note: Use of intrathecal chemotherapy is allowed per Institutional guidelines.
- Prior monoclonal antibody therapy within 4 weeks of planned start of study drug.
- Prior small molecule therapy within 2 weeks or 5 half-lives (whichever is shorter) of planned start of study drug.
- Autologous or allogeneic stem cell transplant within 100 days prior to planned start of study drug.
- Chimeric antigen receptor (CAR) T-cell therapy within 100 days prior to start of study drug (within 60 days prior to start of study drug for Phase 1b).
- Use of systemic corticosteroids outside of dosing limits described below and within 14 days prior to initiation of study treatment excepting those used as prophylaxis for radio diagnostic contrast. Patients with CNSL: no greater than 40 mg/day prednisone, or equivalent, central nervous system lymphoma (CNSL, including both primary and secondary CNSL) patients using greater than 20 mg/day prednisone, or equivalent must be clinically stable at that dose for 14 days. All other diagnoses: no greater than 20 mg/day prednisone or equivalent.
- Use of systemic immunosuppressive drugs other than systemic corticosteroids for any medical condition within 60 days prior to first dose of study drug
- Previously treated with a BTK degrader
- Active, uncontrolled autoimmune hemolytic anemia or autoimmune thrombocytopenia.
Patient has any of the following within 6 months of planned start of study drug:
- Myocardial infarction, unstable angina, unstable symptomatic ischemic heart disease, or placement of a coronary arterial stent
- Uncontrolled atrial fibrillation or other clinically significant arrhythmias, conduction abnormalities, or New York Heart Association (NYHA) class III or IV heart failure
- Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), stroke, or intracranial hemorrhage
- Any other significant cardiac condition (e.g., pericardial effusion, restrictive cardiomyopathy, severe untreated valvular stenosis, severe congenital heart disease, or persistent uncontrolled hypertension defined as systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg despite optimal medical management)
- Bleeding diathesis, or other known risk for acute blood loss.
- History of Grade ≥ 2 hemorrhage within 28 days of planned start of study drug.
- Active known concurrent malignancy or malignancy other than the one under study within the past 3 years. (Exceptions include patients with more recent history of basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast may enroll if they have undergone curative therapy and have no evidence of disease).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1b in MCL
MCL with prior exposure to a BTKi and an anti-CD20 monoclonal antibody (mAb)-based chemo-immunotherapy regimen
|
Oral NX-5948
|
Experimental: Phase 1b in MZL
MZL (EMZL, MALT, NMZL, SMZL) with prior exposure to an anti-CD20 mAb-based chemo-immunotherapy regimen and an additional line of therapy
|
Oral NX-5948
|
Experimental: Phase 1b in PCNSL/SCNSL
PCNSL patients who have progressed or had no response to at least 2 prior lines of therapy, or SCNSL patients meeting criteria for non-CLL/SLL arms above with secondary CNS involvement of lymphoma
|
Oral NX-5948
|
Experimental: Phase 1b in WM
WM with prior exposure to a BTKi and an additional line of therapy
|
Oral NX-5948
|
Experimental: Phase 1b in DLBCL
DLBCL with prior exposure to an anthracycline (unless previously deemed ineligible to receive), an anti-CD20 mAb-based chemoimmunotherapy regimen, and an additional line of therapy
|
Oral NX-5948
|
Experimental: Phase 1b in FL
FL (grade 1-3a) with prior exposure to an anti-CD20 mAb-based chemoimmunotherapy regimen and an additional line of therapy
|
Oral NX-5948
|
Experimental: Phase 1a Dose Escalation
Multiple dose levels of NX-5948 to be evaluated; determination of Maximum Tolerated Dose/Phase 1b recommended dose(s)
|
Oral NX-5948
|
Experimental: Phase 1b in CLL or SLL
CLL or SLL with prior exposure to both a Bruton's tyrosine kinase inhibitor (BTKi) and BCL-2 inhibitor, unless previously deemed ineligible for those therapies.
Patients enrolled in CLL/SLL arm will be randomized to one of two dose levels.
This is the only randomization component in the trial.
|
Oral NX-5948
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with protocol specified dose-limiting toxicities
Time Frame: Up to 24 months
|
Phase 1a
|
Up to 24 months
|
Number of participants with treatment-emergent adverse events (TEAEs); Grade 3, 4, 5 TEAEs, serious adverse events (SAEs), TEAEs leading to study drug discontinuation, deaths due to TEAEs, and all deaths
Time Frame: Up to 5 years
|
Phase 1a/1b
|
Up to 5 years
|
To establish the maximum tolerated dose and/or recommended Phase 1b dose(s)
Time Frame: Up to 24 months
|
Phase 1a
|
Up to 24 months
|
To evaluate the anti-tumor activity of NX-5948 in the dose levels selected for Phase 1b safety expansion based on overall response rate (ORR)
Time Frame: Up to 3 years
|
Phase 1b
|
Up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of response (DOR) as assessed by the Investigator
Time Frame: Up to 5 years
|
Phase 1a/1b
|
Up to 5 years
|
Progression-free survival (PFS) as assessed by the Investigator
Time Frame: Up to 5 years
|
Phase 1a/1b
|
Up to 5 years
|
Complete response (CR) rate / CR with incomplete marrow recovery as assessed by the Investigator
Time Frame: Up to 5 years
|
Phase 1a/1b
|
Up to 5 years
|
Pharmacokinetic (PK) profile of NX-5948: Maximum Serum Concentration
Time Frame: Up to 5 years
|
Phase 1a/1b - Sampling following the first dose, pre- and post-dose at selected cycles and at the end of treatment
|
Up to 5 years
|
Pharmacodynamic (PD) profile of NX-5948: Changes from baseline of BTK levels in B-cells
Time Frame: Up to 5 years
|
Phase 1a/1b - Sampling at screening, following the first dose, pre and post-dose at selected cycles and at the end of treatment
|
Up to 5 years
|
Time to next therapy
Time Frame: Up to 5 years
|
Phase 1a/1b
|
Up to 5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Paula O'Connor, MD, Nurix Therapeutics, Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Disease Attributes
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Neoplasms, Plasma Cell
- Leukemia, Lymphoid
- Leukemia
- Leukemia, B-Cell
- Lymphoma, B-Cell
- Chronic Disease
- Neoplasms
- Lymphoma
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Waldenstrom Macroglobulinemia
- Leukemia, Lymphocytic, Chronic, B-Cell
Other Study ID Numbers
- NX-5948-301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Lymphocytic Leukemia (CLL)
-
AbbVieRecruitingCancer, Chronic Lymphocytic Leukemia (CLL)Korea, Republic of
-
Hackensack Meridian HealthCelgene CorporationTerminatedSmall Lymphocytic Lymphoma | Chronic Lymphocytic Leukemia(CLL)United States
-
Piramal Enterprises LimitedDana-Farber Cancer Institute; Norris Cotton Cancer CenterSuspendedRelapsed/Refractory Chronic Lymphocytic Leukemia (CLL)United States
-
Virginia Commonwealth UniversityGilead SciencesWithdrawnChronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | Refractory Small Lymphocytic Lymphoma | SLL | Relapsed CLL | Relapsed Chronic Lymphocytic Leukemia | Relapsed Small Lymphocytic Lymphoma
-
Tampere University HospitalCompleted
-
AstraZenecaRecruitingChronic Lymphocytic Leukaemia (CLL)Germany
-
University of California, IrvineUnited States Department of DefenseActive, not recruitingAcute Myeloid Leukemia | Chronic Lymphocytic Leukemia | AML, Adult | CLL | CLL, Relapsed | CLL, RefractoryUnited States
-
Memorial Sloan Kettering Cancer CenterPharmacyclics LLC.WithdrawnChronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | CLL/SLL | SLLUnited States
-
Novartis PharmaceuticalsCompletedChronic Lymphocytic Leukemia (CLL) | Leukaemia, Lymphocytic, ChronicUnited States, Belgium, Italy, Greece, Russian Federation, Spain, Poland, Czech Republic
-
AstraZenecaCLL ConsortiumCompletedB Cell Lymphomas | 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), | Prolymphocytic Leukaemia (PLL)United States
Clinical Trials on NX-5948
-
Landos Biopharma Inc.RecruitingUlcerative ColitisUnited States, Belgium, Italy, Poland
-
Landos Biopharma Inc.CompletedUlcerative ColitisUnited States, Ukraine
-
Nymox CorporationCompletedProstate CancerUnited States
-
Abbisko Therapeutics Co, LtdRecruitingSolid TumorUnited States, China
-
Nymox CorporationCompletedBenign Prostatic Hyperplasia | BPH | LUTS | Lower Urinary Tract Symptoms (LUTS)United States
-
NeuronyxCompletedMyocardial InfarctionUnited States
-
Turtle Shell Technologies Pvt. Ltd.RecruitingNo Specific Medical Conditions or Disease StatesUnited States
-
Nymox CorporationCompletedBenign Prostatic HyperplasiaUnited States
-
Nymox CorporationCompletedBenign Prostatic Hyperplasia (BPH)United States
-
Nymox CorporationCompletedBenign Prostatic HyperplasiaUnited States